MX2020007040A - Composiciones que comprenden microbiota coseleccionada y metodos para su uso. - Google Patents

Composiciones que comprenden microbiota coseleccionada y metodos para su uso.

Info

Publication number
MX2020007040A
MX2020007040A MX2020007040A MX2020007040A MX2020007040A MX 2020007040 A MX2020007040 A MX 2020007040A MX 2020007040 A MX2020007040 A MX 2020007040A MX 2020007040 A MX2020007040 A MX 2020007040A MX 2020007040 A MX2020007040 A MX 2020007040A
Authority
MX
Mexico
Prior art keywords
dysbiosis
disorders associated
methods
selected microbiota
compositions
Prior art date
Application number
MX2020007040A
Other languages
English (en)
Inventor
Emma Allen-Vercoe
Original Assignee
Nubiyota Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nubiyota Llc filed Critical Nubiyota Llc
Publication of MX2020007040A publication Critical patent/MX2020007040A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describen en la presente composiciones anhidras que comprenden una microbiota coseleccionada y métodos para utilizarlas para el tratamiento de trastornos asociados con la disbiosis (desequilibrio de la comunidad microbiana que habita un sujeto o habita un tejido particular de un sujeto). En particular, se contemplan composiciones anhidras que comprenden una microbiota coseleccionada y métodos para el tratamiento de trastornos gastrointestinales asociados con la disbiosis. También se contempla en la presente el uso de estas composiciones anhidras que comprenden una microbiota coseleccionada para el tratamiento de trastornos asociados con la disbiosis (por ejemplo, trastornos gastrointestinales asociados con la disbiosis) y el uso de dichas composiciones anhidras que comprenden microbiota coseleccionada en la preparacion de un medicamento para el tratamiento de trastornos asociados con la disbiosis (por ejemplo, trastornos gastrointestinales asociados con la disbiosis).
MX2020007040A 2018-01-05 2019-01-04 Composiciones que comprenden microbiota coseleccionada y metodos para su uso. MX2020007040A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614151P 2018-01-05 2018-01-05
US201862683850P 2018-06-12 2018-06-12
PCT/US2019/012376 WO2019136269A1 (en) 2018-01-05 2019-01-04 Compositions comprising co-selected microbiota and methods for use thereof

Publications (1)

Publication Number Publication Date
MX2020007040A true MX2020007040A (es) 2020-11-11

Family

ID=67144333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007040A MX2020007040A (es) 2018-01-05 2019-01-04 Composiciones que comprenden microbiota coseleccionada y metodos para su uso.

Country Status (18)

Country Link
US (1) US20210069262A1 (es)
EP (1) EP3735224A4 (es)
JP (1) JP2021509904A (es)
KR (1) KR20200136365A (es)
CN (1) CN112087998A (es)
AU (2) AU2019205296B2 (es)
BR (1) BR112020013712A2 (es)
CA (1) CA3087695C (es)
CL (1) CL2020001783A1 (es)
CO (1) CO2020009670A2 (es)
EC (1) ECSP20046307A (es)
IL (1) IL275791A (es)
MX (1) MX2020007040A (es)
PE (1) PE20210322A1 (es)
PH (1) PH12020551038A1 (es)
SG (1) SG11202006450VA (es)
WO (1) WO2019136269A1 (es)
ZA (1) ZA202004678B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
CA3147248A1 (en) * 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
EP4041264A1 (en) 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
WO2021138562A1 (en) * 2019-12-31 2021-07-08 Assembly Biosciences, Inc. Compositions comprising bacterial species and methods related thereto
WO2021145458A1 (ja) * 2020-01-16 2021-07-22 学校法人慶應義塾 胆汁酸を生成するための組成物
CN115915953A (zh) * 2020-04-07 2023-04-04 内盖夫国家生物技术研究所有限公司 改善幼龄反刍动物的健康的方法
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
GB202015687D0 (en) * 2020-10-02 2020-11-18 Microbiotica Ltd Therapeutic composition
WO2022081428A1 (en) * 2020-10-16 2022-04-21 Nubiyota Llc Bacterial compositions and methods of use thereof for treatment of metabolic syndrome
WO2022236365A1 (en) * 2021-05-10 2022-11-17 Microba Ip Pty Ltd Compositions and methods for treating disease
WO2023092141A2 (en) * 2021-11-22 2023-05-25 Dupont Nutrition Biosciences Aps Compositions for metabolic health

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100330151A1 (en) * 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
US20150374761A1 (en) * 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
EP2744890A4 (en) * 2011-09-14 2015-07-08 Univ Kingston METHOD FOR TREATING DISORDERS OF THE GASTROINTESTINAL DEVICE
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN105407728A (zh) * 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2017035191A1 (en) * 2015-08-24 2017-03-02 Nubyiota Llc Systems and methods for enriching a bacterial strain from a target bacterial system
MX2019009861A (es) * 2017-02-23 2020-07-14 Intercept Pharmaceuticals Inc Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.

Also Published As

Publication number Publication date
AU2022201981A1 (en) 2022-04-21
US20210069262A1 (en) 2021-03-11
PH12020551038A1 (en) 2021-09-06
IL275791A (en) 2020-08-31
KR20200136365A (ko) 2020-12-07
CO2020009670A2 (es) 2020-08-31
CN112087998A (zh) 2020-12-15
AU2019205296B2 (en) 2021-12-23
CL2020001783A1 (es) 2021-01-08
EP3735224A1 (en) 2020-11-11
AU2019205296A1 (en) 2020-08-13
PE20210322A1 (es) 2021-02-18
ZA202004678B (en) 2021-09-29
EP3735224A4 (en) 2021-11-03
SG11202006450VA (en) 2020-08-28
JP2021509904A (ja) 2021-04-08
CA3087695C (en) 2023-08-22
CA3087695A1 (en) 2019-07-11
WO2019136269A1 (en) 2019-07-11
BR112020013712A2 (pt) 2020-12-01
ECSP20046307A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
MX2020001187A (es) Composiciones y métodos para la administración de virus adenoasociados.
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
WO2016105984A3 (en) Tissue-based compositions and methods of use thereof
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
SG10201902664RA (en) Combination therapy for treating cancer
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2020006005A (es) Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.
MX2020009733A (es) Composiciones.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
EA202091651A1 (ru) Композиции, включающие совместно выбранную микробиоту, и способы их применения
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
AR113726A1 (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
EP3829643C0 (en) SYNERGISTIC COOPERATIVE COMPOSITIONS FOR SOFT TISSUE AUGMENTATION, DRUG DELIVERY AND RELATED AREAS
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease